A Vega1, S Abad1, U Verdalles1, I Aragoncillo1, K Velazquez2, B Quiroga1, V Escudero3, J M López-Gómez1. 1. Nephrology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 2. Internal Medicine, St Columciles Hospital, Dublin, Ireland. 3. Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Abstract
BACKGROUND: Anemia is a prevalent situation in patients with chronic kidney disease (CKD) and can be well managed with erythropoiesis-stimulating agents (ESAs). Continuous erythropoietin receptor activator (CERA) has a long half-life that allows to be administered once monthly. The lowest recommended dose for patients with non dialysis CKD is 120 μg per month. The objectives were to assess the efficacy of subcutaneous monthly dosing of CERA in CKD stages 4 and 5 not on dialysis, and to determine the equivalent dose to epoetin β and darbepoetin α. METHODS: This is a cohort study. A 30-patient group that ESAs was changed to CERA (μg/month) was used as treatment group. We used the following clinically-based equivalent dosing: epoetin β (IU/week) and darbepoetin α (μg/week): 3000/15= 50; 4000/20=75; 6000/30=100; 8000/40=150. Another group of 30 patients with similar characteristics was used as control group and received the same epoetin β and darbepoetin α doses. RESULTS: The mean CERA initial dose and at 6 months was 81.9 ± 35.2 and 82.0 ± 37.82 μg/month (p=0.37). The mean erythropoietin resistance index (ERI) and hemoglobin at baseline and at 6 months in the CERA group and in the control group were not statistically significant. CONCLUSION: Monthly dosing treatment with CERA is safe and effective. A dose of 75-100 μg/month is enough to maintain stable levels of hemoglobin. Hippokratia 2014; 18 (4): 315-318.
BACKGROUND:Anemia is a prevalent situation in patients with chronic kidney disease (CKD) and can be well managed with erythropoiesis-stimulating agents (ESAs). Continuous erythropoietin receptor activator (CERA) has a long half-life that allows to be administered once monthly. The lowest recommended dose for patients with non dialysis CKD is 120 μg per month. The objectives were to assess the efficacy of subcutaneous monthly dosing of CERA in CKD stages 4 and 5 not on dialysis, and to determine the equivalent dose to epoetin β and darbepoetin α. METHODS: This is a cohort study. A 30-patient group that ESAs was changed to CERA (μg/month) was used as treatment group. We used the following clinically-based equivalent dosing: epoetin β (IU/week) and darbepoetin α (μg/week): 3000/15= 50; 4000/20=75; 6000/30=100; 8000/40=150. Another group of 30 patients with similar characteristics was used as control group and received the same epoetin β and darbepoetin α doses. RESULTS: The mean CERA initial dose and at 6 months was 81.9 ± 35.2 and 82.0 ± 37.82 μg/month (p=0.37). The mean erythropoietin resistance index (ERI) and hemoglobin at baseline and at 6 months in the CERA group and in the control group were not statistically significant. CONCLUSION: Monthly dosing treatment with CERA is safe and effective. A dose of 75-100 μg/month is enough to maintain stable levels of hemoglobin. Hippokratia 2014; 18 (4): 315-318.
Authors: Iain C Macdougall; Richard Robson; Sylvie Opatrna; Xavier Liogier; Anne Pannier; Paul Jordan; Frank C Dougherty; Bruno Reigner Journal: Clin J Am Soc Nephrol Date: 2006-09-13 Impact factor: 8.237
Authors: C Esposito; M Abelli; G Sileno; C Migotto; M Torreggiani; N Serpieri; N Maggi; V Esposito; F Grosjean; M L Scaramuzzi; F Montagna; A D Canton Journal: Transplant Proc Date: 2012-09 Impact factor: 1.066
Authors: William McClellan; Stephen L Aronoff; W Kline Bolton; Sally Hood; Daniel L Lorber; K Linda Tang; Thomas F Tse; Brian Wasserman; Marc Leiserowitz Journal: Curr Med Res Opin Date: 2004-09 Impact factor: 2.580
Authors: Bernard Canaud; Giulio Mingardi; Johann Braun; Pedro Aljama; Peter G Kerr; Francesco Locatelli; Giuseppe Villa; Bruno Van Vlem; Alan W McMahon; Cécile Kerloëguen; Ulrich Beyer Journal: Nephrol Dial Transplant Date: 2008-06-27 Impact factor: 5.992
Authors: Wen-Fang Chiang; Po-Jen Hsiao; Kun-Lin Wu; Hung-Ming Chen; Chi-Ming Chu; Jenq-Shyong Chan Journal: Int J Environ Res Public Health Date: 2022-05-07 Impact factor: 4.614
Authors: Luciano A Pedrini; Adam M Zawada; Anke C Winter; Jenny Pham; Gudrun Klein; Melanie Wolf; Astrid Feuersenger; Pio Ruggiero; Annalisa Feliciani; Carlo Barbieri; Adelheid Gauly; Bernard Canaud; Stefano Stuard Journal: PLoS One Date: 2019-02-22 Impact factor: 3.240